Case # | Age at fingolimod cessation (Y) | Sex | Disease Duration (Y) | Prior DMTs | Treatment duration on fingolimod (Y) | ALC/CD4 at the time of stopping fingolimod (cells/uL) | Wash out period (W) | ALC/CD4 baseline to start DMF (cells/uL) | Treatment duration at time of relapse (W) | ALC/CD4 at the time of relapse (cells/uL) | New/Gd+ lesions at the time of relapse | Response to IV steroid treatment (Yes/No) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 37 | F | 10 | INF-β (Rebif) | 5 | 300/33 | 8 | 1400/ND | 5 | 1700/615 | Brain & Cervical spine | Yes |
2 | 34 | F | 13 | GA (Copaxone) | 4 | 282/<20 | 11 | 644/ND | <1 (4 days) | 626/252 | Brain & Cervical spine | Yes |
3 | 33 | M | 3 | None | 3 | 567/61 | 7 | 1006/389 | 10 | 950/ND | Brain & Cervical spine | Yes |
4 | 50 | F | 4 | INF-β (Rebif & Plegridy) | 1 | 270/<20 | 8 | 1000/551 | 14 | - | Brain, Cervical & Thoracic spine | Yes |
5 | 42 | F | 11 | None | 5.5 | 467/20 | 9 | 1036/295 | 13 | 1241/ND | Brain | Yes |
6 | 33 | F | 8 | GA (Copaxone) & INF-β (Plegridy) | 1 | 509/<20 | 5 | 912/ND | 18 | 1600/ND | Brain & Thoracic spine | Yes |